[Yokohama, Japan, September 4, 2025] – Juro Sciences Inc. (Headquarters: Naka-ku, Yokohama; President & CEO: Hiroshi Nagabukuro), a clinical stage biopharmaceutical developing innovative solutions for underactive bladder (UAB), today announced the completion of its Series B financing. The round was led by Miyako Capital, with participation from SMBC Venture Capital, Gemseki Investment, Vision Incubate, and FFG Venture Business Partners. Together with a grant awarded by the Japan Agency for Medical Research and Development (AMED) under its Drug Discovery Venture Ecosystem Strengthening Program, the total funding amounts to JPY 900 million. This financing will accelerate the development of SFG-02, a promising therapeutic candidate poised to revolutionize the treatment of UAB.

UAB is a serious condition affecting millions of people worldwide. It is characterized by impaired bladder contractility, often caused by aging or central/peripheral neurological disorders, leading to symptoms such as reduced bladder sensation, decreased voided volume, weak urinary flow, frequency, urinary incontinence, urinary retention, and recurrent urinary tract infections. Juro Sciences aims to provide an optimal therapy by targeting the fundamental mechanisms underlying UAB.

Commenting on the financing, Hiroshi Nagabukuro, CEO of Juro Sciences, said:

“We are deeply grateful to our existing investors for their continued support and to our new investors for joining us in this journey. Thanks to the dedication of our team and research partners, we have successfully developed a highly promising transdermal delivery system formulation of SFG-02, supported by strong preclinical data. We are excited to begin our Phase 1 clinical trial this month, and preparations for subsequent trials recruiting UAB patients in Japan and the U.S. starting in 2026 are already underway. This financing brings us closer to delivering a groundbreaking therapy that UAB patients have long awaited.”

Hiroyuki Misawa, Partner at Miyako Capital and a member of the Juro Sciences Board of Directors, added:

“Juro Sciences’ scientific excellence and commitment to patient-centered innovation align perfectly with our investment philosophy. We look forward to the progress and success of this groundbreaking program. The initiation of SFG-02 clinical trials offers great promise for improving the quality of life of patients suffering from UAB.”

Juro Sciences remains strongly committed to high-quality R&D, regulatory compliance, and strategic partnerships, and continues to strive to deliver innovative pharmacotherapy for UAB, for which there are currently no available medicines.

About Juro Sciences Inc.

Juro Sciences is a biopharmaceutical company dedicated to developing innovative therapies for underactive bladder. Leveraging cutting-edge science and a patient-focused approach, the company is committed to alleviating symptoms and improving the quality of life for patients living with UAB.

About SFG-02

SFG-02 is a novel acetylcholinesterase inhibitor with a newly developed transdermal delivery system formulation in development for the treatment of UAB. In multiple preclinical studies, it demonstrated high selectivity for its molecular target and optimal efficacy in animal models of UAB. The non-clinical data to date show a favorable pharmacokinetic profile designed to maximize efficacy while minimizing side effects. A Phase 1 study in healthy volunteers is set to begin this month, followed by proof-of-concept studies in UAB patients in Japan and the U.S. starting in 2026.

For media inquiries regarding the Company or SFG-02, please contact:

info@sfgsci.com